Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000908 · ClinicalTrials.gov registry record

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

A clinical trial of HIV Infections and Pneumonia, Pneumocystis Carinii, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
250
Enrollment target
20
Study locations

NCT00000908 is a study of HIV Infections and Pneumonia, Pneumocystis Carinii that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 250 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000908, a study of HIV Infections and Pneumonia, Pneumocystis Carinii, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
250 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to see how often Pneumocystis carinii pneumonia (PCP) occurs in HIV-positive patients who have stopped taking medications that help prevent PCP. The risk of developing PCP may be decreased when an HIV-positive patient's CD4 cell counts (cells of the immune system which fight infection) are more than 200 cells/mm3. This study looks at whether it is acceptable to stop PCP prevention treatment in these patients.

Study Locations (20)

California

  • Kaiser Foundation Hosp - Harbor City
  • Kaiser Permanente LAMC - Los Angeles
  • Univ of Southern California / LA County USC Med Ctr - Los Angeles
  • Willow Clinic - Menlo Park
  • Univ of California / San Diego Treatment Ctr - San Diego
  • San Francisco AIDS Clinic / San Francisco Gen Hosp - San Francisco
  • San Francisco Gen Hosp - San Francisco
  • Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium - San Jose
  • Marin County Specialty Clinic - San Rafael
  • San Mateo AIDS Program / Stanford Univ - Stanford
  • Stanford Univ Med Ctr - Stanford

Hawaii

  • Queens Med Ctr - Honolulu
  • Univ of Hawaii / Leahi Hosp - Honolulu

Illinois

  • Northwestern Univ Med School - Chicago
  • Cook County Hosp - Chicago

Alabama

  • Univ of Alabama at Birmingham - Birmingham

Colorado

  • Univ of Colorado Health Sciences Ctr - Denver

District of Columbia

  • Howard Univ - Washington D.C.

Florida

  • Univ of Miami School of Medicine - Miami

Georgia

  • Emory Univ - Atlanta

Trial Details

FieldValue
Enrollment Target 250 participants

What the Registry Record Tells You About NCT00000908

The ClinicalTrials.gov registry entry for NCT00000908 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (44% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.

NCT00000908 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Hawaii, Illinois.

Frequently Asked Questions

What is clinical trial NCT00000908 about?

NCT00000908 is a clinical study titled "A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts". The purpose of this study is to see how often Pneumocystis carinii pneumonia (PCP) occurs in HIV-positive patients who have stopped taking medications that help prevent PCP. The risk of developing PCP may be decreased when an HIV-positive patient's CD4 cell counts (cells of the immune system which ...

What is the current status of trial NCT00000908?

This trial is currently completed. The enrollment target is 250 participants.

What conditions does trial NCT00000908 study?

This clinical trial studies the following conditions: HIV Infections, Pneumonia, Pneumocystis Carinii.

Who is sponsoring clinical trial NCT00000908?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000908 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.